Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-stage clinical study of tamoxifen for patients with
well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%)
HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute